The Division Pharmacology was established in 2019 by the appointment of Prof. Dagmar Stoiber-Sakaguchi. The research focus of the division is the identification of underlying molecular mechanisms of tumor formation and progression in acute myeloid leukemia (AML), but also in other human cancer types. The identification of potential (drug) targets may be translated into the assessment of new therapy approaches and new tools for prognosis and diagnosis of AML and other tumor diseases. The research is benefitting from the newly established laboratory that allows state-of-the-art molecular biology research (cell- and tissue culture, bioimaging, protein and DNA/RNA analytics, immunology techniques, in vitro and in vivo studies) at the KL and by the team of nationally and internationally well-connected experts.
Basic Research
Comment to Figure: Type I interferon
JAK/STAT pathway and its influence in acute myeloid leukemia (AML)
Type I interferon as a mediator between tumors and immune system
STAT3 isoforms – the good and the bad in tumor development
Tumor suppressors and oncogenes in lymphoma
Identification and verification of potential targets for new therapeutic options
Applied Research
